Antibodies to amyloid beta

Patent metadata

Field	Value
Publication number	US-12098191-B2
Application number	US-202217673449-A
Country	US
Kind code	B2
Filing date	Feb 16, 2022
Priority date	Oct 15, 2012
Publication date	Sep 24, 2024
Grant date	Sep 24, 2024

Abstract

Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.

First claim

What is claimed is:

1. An isolated antibody molecule that is selective for binding human amyloid beta 1-42 peptide (Aβ1-42) over human amyloid beta 1-40 peptide (Aβ1-40), wherein the antibody molecule comprises a V H domain having an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 524 and a V L domain having an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 533,
wherein the V H domain of the antibody molecule comprises:
a) HCDR1 of SEQ ID NO: 525, HCDR2 of SEQ ID NO: 526, and HCDR3 of SEQ ID NO: 527;
b) wherein FW1 of the V H domain comprises:
a methionine residue at the amino acid position corresponding to position 26 of SEQ ID NO: 524;
a glycine residue at the amino acid position corresponding to position 27 of SEQ ID NO: 524;
an asparagine residue at the amino acid position corresponding to position 28 of SEQ ID NO: 524; and
an asparagine residue at the amino acid position corresponding to position 30 of SEQ ID NO: 524;

and wherein the V L domain of the antibody molecule comprises LCDR1 of SEQ ID NO: 534, LCDR2 of SEQ ID NO: 535, and LCDR3 of SEQ ID NO: 536.

2. The isolated antibody molecule of claim 1 , wherein the antibody molecule comprises a VH domain having an amino acid sequence that is at least 95%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 524 and a VL domain having an amino acid sequence that is at least 95%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 533.

3. The isolated antibody molecule of claim 1 , wherein the antibody molecule is a monoclonal antibody.

4. The isolated antibody molecule of claim 3 , wherein the monoclonal antibody is a recombinant antibody, a humanized antibody, a human antibody, a multispecific antibody, or an antibody fragment thereof.

5. The isolated antibody molecule of claim 4 , wherein the antibody molecule is an scFv.

6. The isolated antibody molecule of claim 4 , wherein the antibody molecule is a Fab.

7. The isolated antibody molecule of claim 3 , wherein the antibody molecule is of the IgG1-, IgG2-, or IgG4-type.

8. The isolated antibody molecule of claim 1 , wherein the antibody molecule is a chimeric antibody.

9. A composition comprising an isolated antibody molecule according to claim 1 , and a pharmaceutically acceptable excipient.

10. A method of treating a human or animal subject having an amyloidosis associated with amyloid beta, the method comprising administering to the subject an antibody according to claim 1 .

11. The method of claim 10 , wherein the treatment at least reduces amyloidosis; treats Alzheimer's disease; improves cognition or reduces cognitive decline in an Alzheimer's disease or Down's syndrome patient; or treats macular degeneration.

12. A method of at least reducing amyloidosis, treating Alzheimer's disease; improving cognition or reducing cognitive decline in an Alzheimer's disease or Down's syndrome patient; and/or treating macular degeneration in an individual, the method comprising administering to the subject an antibody according to claim 1 .

Assignees

• Medimmune Ltd

Inventors

• Groves Maria
• Gustavsson Suzanne
• Höglund Kina
• Lloyd Chris
• Nickson Adrian
• Niva Camilla
• Simon Sylvia
• Lowne David
• Welsh Fraser
• Freskgard Per-Ola

Classifications

• C07K2317/60

  characterized by non-natural combinations of immunoglobulin fragments · CPC title

• C07K2317/567

  Framework region [FR] · CPC title

• C07K2317/515

  Complete light chain, i.e. VL + CL · CPC title

• C07K2317/51

  Complete heavy chain or Fd fragment, i.e. VH + CH1 · CPC title

• A61K2039/505

  comprising antibodies · CPC title